The bill seeks to amend South Dakota's controlled substances law by rescheduling crystalline polymorph psilocybin from Schedule I to Schedule IV, thereby allowing its pharmaceutical composition in FDA-approved drug products to be legally recognized and regulated. This change facilitates the medical use of psilocybin under controlled conditions while explicitly excluding it from Schedule I classification, except for the approved pharmaceutical form. The amendment also updates the language regarding the classification of substances, removing the word "such" and inserting "the" for clarity, and specifies that the exception for peyote use in Native American church services applies only to peyote in its natural state.

Additionally, the bill introduces new substances to Schedule IV, including "Zuranolone" and the specific mention of "the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration." These insertions reflect an effort to regulate emerging substances with potential therapeutic applications while maintaining strict controls on their use. The bill retains the existing framework for controlled substances, ensuring that psychoactive compounds are appropriately classified and regulated to protect public health in light of advancements in medical research and drug approval processes.

Statutes affected:
Introduced, 01/20/2026: 34-20B-14, 34-20B-25